Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

Lomitapide: a review of its use in adults with homozygous familial hypercholesterolemia.

Perry CM.

Am J Cardiovasc Drugs. 2013 Aug;13(4):285-96. doi: 10.1007/s40256-013-0030-7.

PMID:
23720215
2.

Lomitapide for the management of homozygous familial hypercholesterolemia.

deGoma EM.

Rev Cardiovasc Med. 2014;15(2):109-18. Review.

PMID:
25051128
3.

The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia - a post-hoc analysis of a Phase 3, single-arm, open-label trial.

Stefanutti C, Blom DJ, Averna MR, Meagher EA, Theron Hd, Marais AD, Hegele RA, Sirtori CR, Shah PK, Gaudet D, Vigna GB, Sachais BS, Di Giacomo S, du Plessis AM, Bloedon LT, Balser J, Rader DJ, Cuchel M; Phase 3 HoFH Lomitapide Study Investigators.

Atherosclerosis. 2015 Jun;240(2):408-14. doi: 10.1016/j.atherosclerosis.2015.03.014. Epub 2015 Mar 14.

4.

Lomitapide: A novel agent for the treatment of homozygous familial hypercholesterolemia.

Davis KA, Miyares MA.

Am J Health Syst Pharm. 2014 Jun 15;71(12):1001-8. doi: 10.2146/ajhp130592. Review.

PMID:
24865757
5.

Clinical experience of lomitapide therapy in patients with homozygous familial hypercholesterolaemia.

Cuchel M, Blom DJ, Averna MR.

Atheroscler Suppl. 2014 Sep;15(2):33-45. doi: 10.1016/j.atherosclerosissup.2014.07.005. Review.

PMID:
25257075
6.

Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study.

Cuchel M, Meagher EA, du Toit Theron H, Blom DJ, Marais AD, Hegele RA, Averna MR, Sirtori CR, Shah PK, Gaudet D, Stefanutti C, Vigna GB, Du Plessis AM, Propert KJ, Sasiela WJ, Bloedon LT, Rader DJ; Phase 3 HoFH Lomitapide Study investigators.

Lancet. 2013 Jan 5;381(9860):40-6. doi: 10.1016/S0140-6736(12)61731-0. Epub 2012 Nov 2.

7.

Inhibition of hepatic microsomal triglyceride transfer protein - a novel therapeutic option for treatment of homozygous familial hypercholesterolemia.

Vuorio A, Tikkanen MJ, Kovanen PT.

Vasc Health Risk Manag. 2014 May 6;10:263-70. doi: 10.2147/VHRM.S36641. eCollection 2014. Review.

8.
9.

Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia.

Rader DJ, Kastelein JJ.

Circulation. 2014 Mar 4;129(9):1022-32. doi: 10.1161/CIRCULATIONAHA.113.001292. Review. No abstract available.

10.

Mipomersen and lomitapide: Two new drugs for the treatment of homozygous familial hypercholesterolemia.

Gouni-Berthold I, Berthold HK.

Atheroscler Suppl. 2015 May;18:28-34. doi: 10.1016/j.atherosclerosissup.2015.02.005. Review.

PMID:
25936301
11.

Treating homozygous familial hypercholesterolemia in a real-world setting: Experiences with lomitapide.

Roeters van Lennep J, Averna M, Alonso R.

J Clin Lipidol. 2015 Jul-Aug;9(4):607-17. doi: 10.1016/j.jacl.2015.05.001. Epub 2015 May 14.

PMID:
26228681
12.

Individual analysis of patients with HoFH participating in a phase 3 trial with lomitapide: The Italian cohort.

Averna M, Cefal├╣ AB, Stefanutti C, Di Giacomo S, Sirtori CR, Vigna G.

Nutr Metab Cardiovasc Dis. 2016 Jan;26(1):36-44. doi: 10.1016/j.numecd.2015.11.001. Epub 2015 Nov 11.

13.

Emerging low-density lipoprotein therapies: Microsomal triglyceride transfer protein inhibitors.

Goldberg AC.

J Clin Lipidol. 2013 May-Jun;7(3 Suppl):S16-20. doi: 10.1016/j.jacl.2013.03.003. Epub 2013 Mar 26.

14.

LOWER, a registry of lomitapide-treated patients with homozygous familial hypercholesterolemia: Rationale and design.

Blom DJ, Fayad ZA, Kastelein JJ, Larrey D, Makris L, Schwamlein C, Bloeden L, Underberg J; LOWER investigators.

J Clin Lipidol. 2016 Mar-Apr;10(2):273-82. doi: 10.1016/j.jacl.2015.11.011. Epub 2015 Dec 1.

15.
16.

Lomitapide for use in patients with homozygous familial hypercholesterolemia: a narrative review.

Neef D, Berthold HK, Gouni-Berthold I.

Expert Rev Clin Pharmacol. 2016;9(5):655-63. doi: 10.1586/17512433.2016.1162095. Epub 2016 Mar 21. Review.

PMID:
26943823
17.

Lomitapide.

[No authors listed]

Am J Cardiovasc Drugs. 2011 Oct 1;11(5):347-52. doi: 10.2165/11533560-000000000-00000. Review.

PMID:
21846156
18.

Iomitapide (Lojuxta). Use only in homozygous familial hypercholesterolaemia, with caution.

[No authors listed]

Prescrire Int. 2015 Jul;24(162):176-8.

PMID:
26240881
19.

Lomitapide and mipomersen: novel lipid-lowering agents for the management of familial hypercholesterolemia.

Dixon DL, Sisson EM, Butler M, Higbea A, Muoio B, Turner B.

J Cardiovasc Nurs. 2014 Sep-Oct;29(5):E7-E12. doi: 10.1097/JCN.0000000000000104. Review.

PMID:
24231894
20.

Microsomal transfer protein inhibition in humans.

Cuchel M, Rader DJ.

Curr Opin Lipidol. 2013 Jun;24(3):246-50. doi: 10.1097/MOL.0b013e32836139df. Review.

PMID:
23594709

Supplemental Content

Support Center